Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

被引：0
|
作者：
Paulus, Aneel
Manna, Alak
Wang, Hengbang
Chen, Jianyong
Min, Ping
Yin, Yan
Dutta, Navnita
Halder, Nabanita
Ciccio, Gina
Copland, John
Han, Bing
Bai, Longchuan
Liu, Liu
Wang, Mi
McEachern, Donna
Przybranowski, Sally
Yang, Chao-Yie
Stuckey, Jeanne
Wu, Depei
Li, Caixia
Ryan, Jeremy
Letai, Anthony
Ailawadhi, Sikander
Yang, Dajun
Wang, Shaomeng
Chanan-Khan, Asher
Zhai, Yifan
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1549996
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [41] Antitumor activity of novel reversible LSD1 inhibitor in preclinical models of AML and SCLC
    Bae, InHwan
    Kim, WonJeoun
    Kim, JiSook
    Song, JiYoung
    Nam, JungSoo
    Lee, Moonsub
    Byun, Jooyun
    Kim, Hyeongki
    Song, TaeHun
    Hong, Seokhyun
    Lee, KyuHang
    Ahn, YoungGil
    Kim, YoungHoon
    Suh, Kwee Hyun
    CANCER RESEARCH, 2019, 79 (13)
  • [42] TAS1553, a novel class of RNR inhibitor, demonstrates antitumor activity in preclinical models
    Ueno, H.
    Hoshino, T.
    Tsukioka, S.
    Yano, W.
    Suzuki, T.
    Hashimoto, A.
    Miyahara, S.
    Hara, S.
    Ogino, Y.
    Ichikawa, K.
    Matsuo, K.
    Miyadera, K.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E62 - E63
  • [43] The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
    Luo, Qiu-yun
    Yang, Jing
    Di, Tian
    Xia, Zeng-fei
    Zhang, Lin
    Pan, Wen-tao
    Shi, Shan
    Yang, Li-qiong
    Sun, Jian
    Qiu, Miao-zhen
    Yang, Da-jun
    ACTA PHARMACOLOGICA SINICA, 2024, : 1082 - 1096
  • [44] Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity
    Wang, H.
    Wang, G.
    Du, Z.
    Wu, M.
    McEachern, D.
    Aguilar, A.
    Lin, Y.
    Lin, X.
    Wen, J.
    Gu, L.
    Guo, M. I. N. G.
    Zhai, Y.
    Wang, S.
    Yang, D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 176 - 177
  • [45] AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models
    Cidado, Justin
    Secrist, J. Paul
    Gibbons, Francis D.
    Hennessy, Edward J.
    Ioannidis, Stephanos
    Clark, Edwin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [46] MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies
    Halilovic, Ensar
    Chanrion, Maia
    Mistry, Prakash
    Wartmann, Markus
    Qiu, Shumei
    Sanghavi, Sneha
    Chen, Yan
    Lysiak, Gaelle
    Maragno, Ana Leticia
    Pfaar, Ulrike
    Huth, Felix
    Schoumacher, Marie
    Claperon, Audrey
    Kraus-Berthier, Laurence
    Banquet, Sebastien
    Derreal, Alix
    Maacke, Heiko
    Colland, Frederic
    Geneste, Olivier
    Morris, Erick
    Wang, Youzhen
    CANCER RESEARCH, 2019, 79 (13)
  • [47] Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models
    Wang, GuangFeng
    Min, Ping
    Wu, MiaoYi
    Dang, Shuo
    Tang, ChuanYan
    Zhang, Fei
    Guo, Ming
    Wang, Shaomeng
    Deng, Jing
    Fang, Douglas D.
    Yang, DaJun
    Zhai, YiFan
    CANCER RESEARCH, 2018, 78 (13)
  • [48] A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor
    Wu, Y.
    Lakhani, N. J.
    Boyer, M.
    Zhou, Q.
    Rasco, D. W.
    Huang, Y.
    Men, L.
    Li, Y.
    Xia, Z.
    Wang, H.
    Ji, J.
    Lu, B.
    He, Z.
    Dong, Q.
    Yang, D.
    Zhai, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1048 - S1049
  • [49] PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer
    Huglo, Alisee
    Rebello, Richard
    Lawrence, Mitchell
    Risbridger, Gail
    Drygin, Denis
    Haddach, Mustapha
    Hannan, Katherine
    Hannan, Ross
    Furic, Luc
    CANCER RESEARCH, 2022, 82 (12)
  • [50] MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
    Douglas D. Fang
    Qiuqiong Tang
    Yanhui Kong
    Tao Rong
    Qixin Wang
    Na Li
    Xu Fang
    Jiaxing Gu
    Dengkun Xiong
    Yan Yin
    Jing Deng
    Dajun Yang
    Yifan Zhai
    Cell Death Discovery, 7
12345